Citigroup’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.06M | Buy |
134,298
+46,973
| +54% | +$300K | ﹤0.01% | 3409 |
|
|
2026
Q1 | $506K | Sell |
87,325
-11,421
| -12% | -$75.7K | ﹤0.01% | 3533 |
|
|
2025
Q4 | $775K | Buy |
98,746
+28,491
| +41% | +$224K | ﹤0.01% | 3301 |
|
|
2025
Q3 | $572K | Sell |
70,255
-7,279
| -9% | -$48.4K | ﹤0.01% | 3513 |
|
|
2025
Q2 | $362K | Sell |
77,534
-40,674
| -34% | -$186K | ﹤0.01% | 3801 |
|
|
2025
Q1 | $649K | Sell |
118,208
-14,238
| -11% | -$57.5K | ﹤0.01% | 3530 |
|
|
2024
Q4 | $449K | Buy |
132,446
+13,019
| +11% | +$41.9K | ﹤0.01% | 3907 |
|
|
2024
Q3 | $340K | Buy |
119,427
+74,082
| +163% | +$190K | ﹤0.01% | 3986 |
|
|
2024
Q2 | $102K | Buy |
45,345
+3,583
| +9% | +$7.22K | ﹤0.01% | 4200 |
|
|
2024
Q1 | $92.3K | Buy |
41,762
+19,818
| +90% | +$51.3K | ﹤0.01% | 4329 |
|
|
2023
Q4 | $51.6K | Buy |
21,944
+20,147
| +1,121% | +$37.2K | ﹤0.01% | 4500 |
|
|
2023
Q3 | $3.34K | Sell |
1,797
-40,172
| -96% | -$92K | ﹤0.01% | 4831 |
|
|
2023
Q2 | $110K | Buy |
41,969
+40,420
| +2,609% | +$103K | ﹤0.01% | 4201 |
|
|
2023
Q1 | $2.52K | Sell |
1,549
-1,006
| -39% | -$1.26K | ﹤0.01% | 5063 |
|
|
2022
Q4 | $3.4K | Sell |
2,555
-997
| -28% | -$1.41K | ﹤0.01% | 5114 |
|
|
2022
Q3 | $6K | Sell |
3,552
-5,809
| -62% | -$9.61K | ﹤0.01% | 5183 |
|
|
2022
Q2 | $14K | Sell |
9,361
-325,789
| -97% | -$687K | ﹤0.01% | 5204 |
|
|
2022
Q1 | $858K | Buy |
335,150
+331,429
| +8,907% | +$810K | ﹤0.01% | 3110 |
|
|
2021
Q4 | $11K | Sell |
3,721
-2,023
| -35% | -$4.37K | ﹤0.01% | 5548 |
|
|
2021
Q3 | $14K | Sell |
5,744
-1,590
| -22% | -$4.62K | ﹤0.01% | 5386 |
|
|
2021
Q2 | $30K | Sell |
7,334
-453
| -6% | -$1.73K | ﹤0.01% | 5092 |
|
|
2021
Q1 | $35K | Sell |
7,787
-6,234
| -44% | -$33.6K | ﹤0.01% | 4918 |
|
|
2020
Q4 | $69K | Buy |
14,021
+3,939
| +39% | +$19.7K | ﹤0.01% | 5819 |
|
|
2020
Q3 | $60K | Sell |
10,082
-1,034
| -9% | -$4.13K | ﹤0.01% | 5473 |
|
|
2020
Q2 | $29K | Buy |
11,116
+1,644
| +17% | +$5.72K | ﹤0.01% | 6348 |
|
|
2020
Q1 | $18K | Sell |
9,472
-2,192,367
| -100% | -$9.43M | ﹤0.01% | 6767 |
|
|
2019
Q4 | $15.5M | Buy |
2,201,839
+2,198,541
| +66,663% | +$18.2M | 0.01% | 1127 |
|
|
2019
Q3 | $33K | Sell |
3,298
-5,762
| -64% | -$64.7K | ﹤0.01% | 6407 |
|
|
2019
Q2 | $103K | Buy |
9,060
+3,201
| +55% | +$33.6K | ﹤0.01% | 5852 |
|
|
2019
Q1 | $59K | Buy |
5,859
+4,395
| +300% | +$56.3K | ﹤0.01% | 6201 |
|
|
2018
Q4 | $25K | Sell |
1,464
-386
| -21% | -$7.74K | ﹤0.01% | 6765 |
|
|
2018
Q3 | $33K | Buy |
+1,850
| New | +$40.2K | ﹤0.01% | 6837 |
|
Other funds holding XERS
RA
Citigroup's XERS Position: Q2 2026 in Review
Citigroup increased its Xeris Biopharma Holdings (XERS) stake by 54% in Q2 2026, buying an estimated $300K and bringing the position to 134,298 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #3409.
Citigroup first reported a position in XERS in Q3 2018 and has held it in 32 quarters since. The position peaked at $15.5M in Q4 2019. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.
- Citigroup held 134,298 shares of Xeris Biopharma Holdings worth $1.06M as of Q2 2026.
- Citigroup bought 46,973 Xeris Biopharma Holdings shares in Q2 2026, an estimated $300K.
- Xeris Biopharma Holdings made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3409 holding.
- Citigroup first reported a position in Xeris Biopharma Holdings in Q3 2018 and has held it in 32 quarters since.
- Citigroup's Xeris Biopharma Holdings position peaked at $15.5M in Q4 2019.
- 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.